TR200003248T2 - İkame edilmiş sülfonilsiyanamidler, üretimi için yöntem ve ilaç olarak kullanımları. - Google Patents

İkame edilmiş sülfonilsiyanamidler, üretimi için yöntem ve ilaç olarak kullanımları.

Info

Publication number
TR200003248T2
TR200003248T2 TR2000/03248T TR200003248T TR200003248T2 TR 200003248 T2 TR200003248 T2 TR 200003248T2 TR 2000/03248 T TR2000/03248 T TR 2000/03248T TR 200003248 T TR200003248 T TR 200003248T TR 200003248 T2 TR200003248 T2 TR 200003248T2
Authority
TR
Turkey
Prior art keywords
conditions
sciatic
formula
treatment
sulfonylcyanamides
Prior art date
Application number
TR2000/03248T
Other languages
English (en)
Turkish (tr)
Inventor
Weichert Andreas
Jochen Lang Hans
Petry Stefan
Schwark Jan-Robert
Kleemann Heinz-Werner
Faber Sabine
Jansen Hans-Willi
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200003248T2 publication Critical patent/TR200003248T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
TR2000/03248T 1998-05-06 1999-04-30 İkame edilmiş sülfonilsiyanamidler, üretimi için yöntem ve ilaç olarak kullanımları. TR200003248T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19820064A DE19820064A1 (de) 1998-05-06 1998-05-06 Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Publications (1)

Publication Number Publication Date
TR200003248T2 true TR200003248T2 (tr) 2001-03-21

Family

ID=7866747

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03248T TR200003248T2 (tr) 1998-05-06 1999-04-30 İkame edilmiş sülfonilsiyanamidler, üretimi için yöntem ve ilaç olarak kullanımları.

Country Status (26)

Country Link
US (1) US6573288B1 (enExample)
EP (1) EP1076651B1 (enExample)
JP (1) JP4546644B2 (enExample)
KR (1) KR20010043304A (enExample)
CN (1) CN1177829C (enExample)
AR (1) AR016255A1 (enExample)
AT (1) ATE293606T1 (enExample)
AU (1) AU756844B2 (enExample)
BR (1) BR9911009A (enExample)
CA (1) CA2331863A1 (enExample)
DE (3) DE19820064A1 (enExample)
DK (1) DK1076651T3 (enExample)
ES (1) ES2241326T3 (enExample)
HR (1) HRP20000746A2 (enExample)
HU (1) HU225377B1 (enExample)
ID (1) ID28020A (enExample)
IL (1) IL139264A (enExample)
NO (1) NO317886B1 (enExample)
NZ (1) NZ507964A (enExample)
PL (1) PL344041A1 (enExample)
PT (1) PT1076651E (enExample)
RU (1) RU2221789C2 (enExample)
SK (1) SK16582000A3 (enExample)
TR (1) TR200003248T2 (enExample)
WO (1) WO1999057102A1 (enExample)
ZA (1) ZA200006166B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10206354A1 (de) * 2002-02-14 2003-08-28 Aventis Pharma Gmbh Verwendung von Inhibitoren des Natrium-abhängigen Chlorid-Bicarbonat-Austauschers zur Behandlung von thrombotischen und inflammatorischer Erkrankungen
US20030220383A1 (en) * 2002-02-14 2003-11-27 Aventis Pharma Deutschland Gmbh Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
ITTO20060575A1 (it) * 2006-08-02 2008-02-03 Univ Pisa Inibitori di zinco proteinasi tioaril sostituiti e loro usi
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
IL98319A (en) * 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
TW215434B (enExample) * 1992-03-07 1993-11-01 Hoechst Ag
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
FR2711368B1 (fr) * 1993-09-16 1996-01-05 Roussel Uclaf Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19804251A1 (de) 1998-02-04 1999-08-05 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
ATE293606T1 (de) 2005-05-15
HRP20000746A2 (en) 2001-06-30
NZ507964A (en) 2003-06-30
SK16582000A3 (sk) 2001-06-11
DK1076651T3 (da) 2005-08-15
IL139264A0 (en) 2001-11-25
IL139264A (en) 2004-07-25
NO317886B1 (no) 2004-12-27
CA2331863A1 (en) 1999-11-11
AU5947999A (en) 1999-11-23
CN1305463A (zh) 2001-07-25
NO20005549L (no) 2001-01-05
US6573288B1 (en) 2003-06-03
AR016255A1 (es) 2001-06-20
ES2241326T3 (es) 2005-10-16
ZA200006166B (en) 2001-09-26
AU756844B2 (en) 2003-01-23
ID28020A (id) 2001-05-03
EP1076651A1 (de) 2001-02-21
HK1038008A1 (en) 2002-03-01
CN1177829C (zh) 2004-12-01
PT1076651E (pt) 2005-08-31
WO1999057102A1 (de) 1999-11-11
EP1076651B1 (de) 2005-04-20
DE19820064A1 (de) 1999-11-11
DE59911949D1 (de) 2005-05-25
JP2002513785A (ja) 2002-05-14
HU225377B1 (en) 2006-10-28
KR20010043304A (ko) 2001-05-25
RU2221789C2 (ru) 2004-01-20
NO20005549D0 (no) 2000-11-03
HUP0102459A2 (hu) 2002-03-28
JP4546644B2 (ja) 2010-09-15
PL344041A1 (en) 2001-09-24
DE19980787D2 (de) 2001-03-22
BR9911009A (pt) 2001-02-13
HUP0102459A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
EA200000409A1 (ru) Соединение, фармацевтическая композиция, способ ингибирования гибели клетки в одной клетке или ткани, способ лечения или снижения клеточной смерти, способ лечения или профилактики поликистозного заболевания почек или анемии/эритропоэза у животных, способ защиты органа или ткани млекопитающего от гибели клеток, способ снижения или профилактики гибели клеток в органе или ткани донора после их трансплантации, способ снижения или предотвращения гибели спермы или яйцеклеток
EA200200768A1 (ru) Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
NO20020938D0 (no) Substituerte alfa-hydroksysyre-caspaseinhibitorer og deres anvendelse
DE60035037D1 (de) Caspase inhibitoren und ihre verwendung
BR9811988A (pt) Derivados de n-alcanoilfenilalanina
DK0950057T3 (da) 3-pyridylenantiomerer og deres anvendelse som analgetika
BR0307279A (pt) Métodos para fechar e abrir um semi-canal e uma célula, tecido orgãnico ou órgão, para prevenir ou tratar o estresse de tecido orgãnico ou órgão em um mamìfero, para aumentar a comunicação intracelular da junção com intervalo em uma célula, tecido orgãnico ou órgão, para tratamento de queimaduras, de tromboses, da acidose respitatória e metabólica, e da arritmia focal, para tratar e prevenir o dano de célula e tecido orgãnico resultante de nìveis elevados de glicose no sangue, para tratamento da fibrilação atrial crÈnica e da epilepsia, para criar composto candidatos que modulem a função de semi-canal, para citoproteger tecido orgãnico ou um órgão de um mamìfero em necessidade de tal tratamento, e para prevenir ou tratar o dano da reperfusão em um mamìfero
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
ATE336480T1 (de) Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EP1076563A4 (en) DIPEPTID CASPASE INHIBITORS AND THEIR USE
DE69824183T2 (de) N-alkanoylphenylalaninderivate
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
PA8477001A1 (es) Inhibidores no peptidilicos de la union a las celulas dependientes de la vla-4 utiles en el tratamiento de enfermedades inflamatorias autoinmunes y respiratorias
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
BR0211559A (pt) Compostos, composições de ligantes tetracìclicos terapeuticamente úteis e seus usos
ATE343575T1 (de) Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
BR0213417A (pt) Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
TR200003248T2 (tr) İkame edilmiş sülfonilsiyanamidler, üretimi için yöntem ve ilaç olarak kullanımları.
BR9916505A (pt) O emprego de inibidores da troca desódio-hidrogênio para a preparação de ummedicamento para evitar disfunções de órgãoscondicionadas pela idade, doenças condicionadaspela idade e para o prolongamento da vida
DK0720598T3 (da) Phenoxyphenylcyclopentenyl-hydroxyurinstoffer
DE69630785D1 (de) Carbazole zur behandlung von mikrobiellen infektionen